Vitamin D and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD): An Update
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Non-alcoholic fatty liver disease (NAFLD) is the first cause of chronic liver disease worldwide; it ranges from simple steatosis to steatohepatitis (NASH) and, potentially, cirrhosis and hepatocarcinoma. NAFLD is also an independent risk factor for type 2 diabetes, cardiovascular diseases, and mortality. As it is largely associated with insulin resistance and related disorders, NAFLD has been recently re-named as Metabolic dysfunction-Associated Fatty Liver Disease (MAFLD). At present, there are no approved pharmacological treatments for this condition. Vitamin D is a molecule with extensive anti-fibrotic, anti-inflammatory, and insulin-sensitizing properties, which have been proven also in hepatic cells and is involved in immune-metabolic pathways within the gut–adipose tissue–liver axis. Epidemiological data support a relationship hypovitaminosis D and the presence of NAFLD and steatohepatitis (NASH); however, results from vitamin D supplementation trials on liver outcomes are controversial. This narrative review provides an overview of the latest evidence on pathophysiological pathways connecting vitamin D to NAFLD, with emphasis on the effects of vitamin D treatment in MAFLD by a nonsystematic literature review of PubMed published clinical trials. This article conforms to the Scale for Assessment of Narrative Review Articles (SANRA) guidelines. Evidence so far available supports the hypothesis of potential benefits of vitamin D supplementation in selected populations of NAFLD patients, as those with shorter disease duration and mild to moderate liver damage.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Eslam, M., Newsome, P. N., Sarin, S. K., Anstee, Q. M., Targher, G., Romero-Gomez, M., Zelber-Sagi, S., Wai-Sun Wong, V., Dufour, J.-F., Schattenberg, J. M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.039 · Cited by 4,472
SANRA—a scale for the quality assessment of narrative review articles
Baethge, C., Goldbeck-Wood, S., & Mertens, S. (2019) · Research Integrity and Peer Review · doi:10.1186/s41073-019-0064-8 · Cited by 3,469
Long-term follow-up of patients with NAFLD and elevated liver enzymes
Ekstedt, M., Franzén, L. E., Mathiesen, U. L., Thorelius, L., Holmqvist, M., Bodemar, G., & Kechagias, S. (2006) · Hepatology · doi:10.1002/hep.21327 · Cited by 2,302 · cited 1×
“As a vicious circle, once MAFLD is established it increases the hepatic insulin resistance, which, in turn, may trigger, in 30–40% of cases, MAFLD evolution towards steatohepatitis (NASH), and eventually, cirrhosis, liver failure, and hepatocarcinoma [4,5].”
BackgroundRisk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease
Targher, G., Day, C. P., & Bonora, E. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0912063 · Cited by 1,907 · cited 1×
“MAFLD also promotes systemic low-grade inflammation and impairs insulin sensitivity in extra-hepatic tissues [6].”
BackgroundNonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases
Samuel, V. T., & Shulman, G. I. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2017.08.002 · Cited by 745 · cited 1×
“As a vicious circle, once MAFLD is established it increases the hepatic insulin resistance, which, in turn, may trigger, in 30–40% of cases, MAFLD evolution towards steatohepatitis (NASH), and eventually, cirrhosis, liver failure, and hepatocarcinoma [4,5].”
BackgroundWang, J., Thingholm, L. B., Skiecevičienė, J., Rausch, P., Kummen, M., Hov, J. R., Degenhardt, F., Heinsen, F.-A., Rühlemann, M. C., Szymczak, S., et al. (2016) · Nature Genetics · doi:10.1038/ng.3695 · Cited by 625
A vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic response
Ding, N., Yu, R. T., Subramaniam, N., Sherman, M. H., Wilson, C., Rao, R., Leblanc, M., Coulter, S., He, M., Scott, C., et al. (2013) · Cell · doi:10.1016/j.cell.2013.03.028 · Cited by 622 · cited 2×
“Mice knocked-out for the VDR gene spontaneously developed hepatic damage and fibrosis toward to frank cirrhosis [34].”
BackgroundFrom NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options
Gastaldelli, A., & Cusi, K. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.07.002 · Cited by 455
Abramovitch, S., Dahan-Bachar, L., Sharvit, E., Weisman, Y., Tov, A. B., Brazowski, E., & Reif, S. (2011) · Gut · doi:10.1136/gut.2010.234666 · Cited by 286
Rosso, C., Kazankov, K., Younes, R., Esmaili, S., Marietti, M., Sacco, M., Carli, F., Gaggini, M., Salomone, F., Møller, H. J., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.06.031 · Cited by 217
Dawson-Hughes, B., Staten, M. A., Knowler, W. C., Nelson, J., Vickery, E. M., LeBlanc, E. S., Neff, L. M., Park, J., & Pittas, A. G. (2020) · Diabetes Care · doi:10.2337/dc20-1765 · Cited by 192 · cited 5×
“Finally, MAFLD increases the risk of type 2 diabetes (T2D) and diabetes’ complications and is an established risk factor for cardiovascular morbidity and mortality [7].”
BackgroundInfluentialDella Corte, C., Carpino, G., De Vito, R., De Stefanis, C., Alisi, A., Cianfarani, S., Overi, D., Mosca, A., Stronati, L., Cucchiara, S., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0168216 · Cited by 112
Cimini, F. A., Barchetta, I., Carotti, S., Bertoccini, L., Baroni, M. G., Vespasiani-Gentilucci, U., Cavallo, M.-G., & Morini, S. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i19.3407 · Cited by 101
Abramovitch, S., Sharvit, E., Weisman, Y., Bentov, A., Brazowski, E., Cohen, G., Volovelsky, O., & Reif, S. (2015) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00132.2013 · Cited by 82
Sick fat: the good and the bad of old and new circulating markers of adipose tissue inflammation
Barchetta, I., Cimini, F. A., Ciccarelli, G., Baroni, M. G., & Cavallo, M. G. (2019) · Journal of Endocrinological Investigation · doi:10.1007/s40618-019-01052-3 · Cited by 77
Self-citationBarchetta, I., Cimini, F. A., Capoccia, D., De Gioannis, R., Porzia, A., Mainiero, F., Di Martino, M., Bertoccini, L., De Bernardinis, M., Leonetti, F., et al. (2017) · Journal of the Endocrine Society · doi:10.1210/js.2017-00108 · Cited by 60
Self-citation
Cited by
The role of vitamin D and vitamin D binding protein in chronic liver diseases
Pop, T. L., Sîrbe, C., Benţa, G., Mititelu, A., & Grama, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810705 · Cited by 105
“Some data suggest that the efficacy of vitamin D supplementation in MAFLD is linked to its role in glucose tolerance and insulin resistance.”
BackgroundInfluential
Metadata
- Authors
- Barchetta, I., Cimini, F. A., & Cavallo, M. G.
- Venue
- Nutrients
- Publisher
- MDPI AG
- Published
- 2020-10-28
- Volume
- 12
- Issue
- 11
- Pages
- 3302
- ISSN
- 2072-6643 (ISSN-L)
- OpenAlex
- W3096075211
- Cited by
- 186
- References
- 18
- FWCI
- 13.52
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.